Drug Profile
Research programme: diabetes therapeutics - Astellas Pharma
Alternative Names: AS 1535907; AS 1669058; AS 1907417; GPR119 agonists - Astellas PharmaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Oxides; Pyridines; Pyrimidines
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Japan (PO)
- 26 Aug 2010 Pharmacodynamics data from preclinical studies for Type-2 diabetes mellitus presented at the 240th American Chemical Society National Meeting (240th-ACS-2010)
- 22 Jun 2009 Pharmacodynamics data from preclinical studies for Type-2 diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)